JP2025508337A5 - - Google Patents
Info
- Publication number
- JP2025508337A5 JP2025508337A5 JP2024544912A JP2024544912A JP2025508337A5 JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5 JP 2024544912 A JP2024544912 A JP 2024544912A JP 2024544912 A JP2024544912 A JP 2024544912A JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- antisense oligonucleotide
- conjugated antisense
- exon
- following sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303577P | 2022-01-27 | 2022-01-27 | |
| US63/303,577 | 2022-01-27 | ||
| PCT/CA2023/050096 WO2023141710A1 (en) | 2022-01-27 | 2023-01-26 | Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508337A JP2025508337A (ja) | 2025-03-26 |
| JP2025508337A5 true JP2025508337A5 (enExample) | 2026-02-03 |
Family
ID=87469898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544912A Pending JP2025508337A (ja) | 2022-01-27 | 2023-01-26 | 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114464A1 (enExample) |
| EP (1) | EP4469576A4 (enExample) |
| JP (1) | JP2025508337A (enExample) |
| CN (1) | CN119137274A (enExample) |
| CA (1) | CA3243078A1 (enExample) |
| WO (1) | WO2023141710A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9801948B2 (en) * | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
| EP3997228A4 (en) * | 2019-07-09 | 2024-05-15 | The Governors of the University of Alberta | SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE |
| WO2021119756A1 (en) * | 2019-12-20 | 2021-06-24 | PYC Therapeutics Limited | Novel cellular delivery methods |
-
2023
- 2023-01-26 CA CA3243078A patent/CA3243078A1/en active Pending
- 2023-01-26 CN CN202380028701.3A patent/CN119137274A/zh active Pending
- 2023-01-26 WO PCT/CA2023/050096 patent/WO2023141710A1/en not_active Ceased
- 2023-01-26 JP JP2024544912A patent/JP2025508337A/ja active Pending
- 2023-01-26 EP EP23745765.0A patent/EP4469576A4/en active Pending
- 2023-01-26 US US18/730,955 patent/US20250114464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508337A5 (enExample) | ||
| JP2023123491A5 (enExample) | ||
| JP6954843B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| JP6077543B2 (ja) | ペプチド | |
| JP4974890B2 (ja) | ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法 | |
| JP2023544683A5 (enExample) | ||
| JPWO2023026994A5 (enExample) | ||
| JP2018530560A5 (enExample) | ||
| JP2010533171A5 (enExample) | ||
| US20240254464A1 (en) | Cleavage-inactive cas12f1, cleavage-inactive cas12f1-based fusion protein, crispr gene-editing system comprising same, and preparation method and use thereof | |
| JP2004528266A (ja) | 薬物送達用組成物 | |
| CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
| FI4536686T3 (fi) | Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi | |
| Altrichter et al. | Simultaneous targeting of two master regulators of apoptosis with dual-action PNA–and DNA–peptide conjugates | |
| JP2019523302A5 (enExample) | ||
| WO2001076636A2 (en) | Pharmaceutical composition of modified pna molecules | |
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| CN118043461A (zh) | 方法 | |
| JP2022511055A5 (enExample) | ||
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| WO1996035705A1 (en) | Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion | |
| WO2025090254A1 (en) | Adnp syndrome antisense treatment | |
| WO2005076732A2 (en) | Peptide-pna chimera targeting inducible nitric oxide synthase | |
| HK40078573A (en) | Antisense nucleic acid that induces skipping of exon 50 |